<DOC>
	<DOCNO>NCT01705509</DOCNO>
	<brief_summary>This proof concept trial use ranolazine , medication , patient know Coronary Artery Disease reduce leave ventricular function , EF &lt; 40 % . We propose ranolazine therapy result demonstrative improvement cardiac function objectively assess use parameter measure CPET . We propose demonstrative improvement CPET parameter ranolazine translate improve patient outcome patient population .</brief_summary>
	<brief_title>The Effects Ranolazine CPET Parameters Ischemic Cardiomyopathy Patients ( ERIC )</brief_title>
	<detailed_description>Selected patient undergo CPET evaluation . The initial CPET identify patient underlie ischemia serve baseline study . Ischemia assess use : 1 ) peak VO2 : measure peak transport O2 tissue O2 extraction blood maximal ; 2 ) anaerobic threshold ( AT ) : measure sustainable work capacity unit VO2 ; 3 ) O2-pulse measurement AT peak VO2 : estimate stroke volume level exercise ; 4 ) relationship O2 uptake work rate ( ΔVO2/ΔWR ) : provide information ability cardiac output increase . Patients whoseCPET result meet criterion ischemia start Ranexa 500mg BID advance within one week +/-4 day 1000mg BID . A second CPET perform 4 week +/- 4 day maximum therapy . CPET result therapy undergo statistical comparison . The initial treatment CPET measurement serve control ass change find therapy . No medication change revascularization procedure occur study . If patient require undergo medication change revascularization procedure , exclude study . Patients contact completion week one prior titration , end week two ensure tolerance compliance 1000mg BID dose . Patients perform second CPET study week four +/- 1 week . The trial medication assess counted ensure patient take allotted pill count duration study . Patients find noncompliant less 80 % exclude study .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Patients &gt; 18 year age enrol trial . Stable patient without hospitalization , medication change cardiac intervention within one month study enrol . Patients must able complete CPET protocol must demonstrable ischemia initial CPET evaluation . Patients must document ejection fraction &lt; 40 % a. LV function assess via : i. Echocardiogram ii . MUGA Nuclear Perfusion Scan iii . Left ventriculogram Patients must Ranexa naive without contraindication Ranexa therapy . QTc &gt; 500 msec rest EKG Hepatic Impairment ( ChildPugh class A , B C ) Have receive prior treatment ranolazine Treatment QT prolong drug class 1A ( e.g. , quinidine ) , class III ( e.g. , sotalol , dofetilide ) antiarrhythmic , amiodarone antipsychotic ( e.g. , thioridazine , ziprasidone ) Treatment potent moderately potent CYP3A inhibitor include ketoconazole azole antifungal , diltiazem , verapamil , macrolide antibiotic , HIV protease inhibitor consumption grapefruit juice grapefruit juice contain product Have participate another trial investigational device drug within 30 day screen Have end stage renal disease require dialysis Have chronic illness likely effect compliance protocol Have second third degree atrioventricular block absence function ventricular pacemaker Have uncontrolled clinically significant cardiac arrhythmia , history ventricular fibrillation , torsade de pointes , lifethreatening ventricular arrhythmia Uncontrolled HTN define BP &gt; /= 160/100 mm Hg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>The Effects Ranolazine CPET Parameters Ischemic</keyword>
	<keyword>Cardiomyopathy Patients</keyword>
</DOC>